Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D alpha and beta chains.
Major histocompatibility complex (MHC) class II combined immunodeficiency (CID), also known as type II bare lymphocyte syndrome, is an autosomal recessive genetic disorder characterized by the complete lack of expression of MHC class II antigens. The defect results from a coordinated lack of transcription of all class II genes. Cell fusion studies using many patient- and experimentally derived class II-negative cell lines have identified four distinct genetic complementation groups. In this report, we present genetic evidence that cell lines derived from two newly described MHC class II-deficient patients, KER and KEN, represent a fifth complementation group. In addition, the KER and KEN cell lines display a unique pattern of dyscoordinate regulation of their MHC class II genes, which is reflected in a new phenotype of in vivo promoter occupancy as revealed by in vivo genomic footprinting. These data point to a new defect that can result in the MHC class II-deficient phenotype.
Douhan
J
J
Department of Cancer Biology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Hauber
I
I
Eibl
M M
MM
Glimcher
L H
LH
D002459:Cell Fusion; D002460:Cell Line; D002874:Chromosome Mapping; D018983:DNA Footprinting; D005786:Gene Expression Regulation; D005802:Genes, MHC Class II; D005808:Genes, Recessive; D006681:HLA-D Antigens / Q000096:biosynthesis / Q000235:genetics*; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D016130:Immunophenotyping; D008214:Lymphocytes / Q000276:immunology*; D046911:Macromolecular Substances; D016511:Severe Combined Immunodeficiency / Q000235:genetics* / Q000276:immunology*; D014158:Transcription, Genetic
D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D046911:Macromolecular Substances